TITLE

Postthrombolytic High-Risk Syndrome

AUTHOR(S)
Zatuchni, Jacob
PUB. DATE
August 1988
SOURCE
Angiology;Aug1988, Vol. 39 Issue 8, p773
SOURCE TYPE
Academic Journal
DOC. TYPE
Letter
ABSTRACT
Presents a letter to the editor about post-thrombolytic high-risk syndrome.
ACCESSION #
16474804

 

Related Articles

  • Intrapleural Fibrinolytics for Pleural Infection: Optimizing Dosing for Future Trials. Heppler, J. Scott // Mayo Clinic Proceedings;Aug2007, Vol. 82 Issue 8, p1016 

    A letter to the editor is presented in response to the article regarding the use of intrapleural tissue-type plasminogen activator (tPA) for pleural infection.

  • In reply. Levinson, Gary M.; Pennington, Daniel W. // Mayo Clinic Proceedings;Aug2007, Vol. 82 Issue 8, p1016 

    A response by Dr. Thomas J. Romano to a letter to the editor about the article which discusses the use of intrapleural tissue-type plasminogen activator (tPA) for pleural infection is presented.

  • The author's reply.  // Heart;Dec2009, Vol. 95 Issue 24, p16 

    An abstract of the author's reply to the article about the trials and pre-hospital treatment with thrombolytic drugs is presented.

  • The authors' reply:. Schömig, A.; Sarafoff, N.; Seyfarth, M. // Heart;Jan2010, Vol. 96 Issue 1, p73 

    A letter to the editor is presented in response to the article "Triple antithrombotic management after stent implantation: when and how?," by W. Dewilde and J. Ten Berg.

  • Thrombolytic drugs: If one doesn't work, try another.  // Geriatrics;Aug94, Vol. 49 Issue 8, p58 

    Presents the summary of findings from the study entitled `Differences in Clot Lysis among Patients Demonstrated in vitro with Three Thrombolytic Agents (Tissue-Type Plasminogen Activator, Streptokinase and Urokinase' conducted by D.R. Musselman and others published in the 1994 issue of `American...

  • ERRATUM.  // Angiology;Nov1975, Vol. 26 Issue 10, p758 

    Presents a correction to the article "Thrombolytic Treatment With I.V. Brinase of Advanced Arterial Obliterative Disease of the Limbs" that was published in the previous issue of the journal "Angiology."

  • FDA CLEARS THROMBOLYTIC DRUG FOR PHASE II CLINICAL TRIAL.  // Worldwide Biotech;May2002, Vol. 14 Issue 5, p6 

    Reports on the approval by the U.S. Food and Drug Administration for the testing of British Biotech's novel thrombolytic agent, BB-10153, in heart attack patients.

  • Intraoperative use of thrombolytic agents. Earnshaw, Jonothan J.; Beard, Jonathan // BMJ: British Medical Journal (International Edition);9/11/93, Vol. 307 Issue 6905, p638 

    Focuses on the use of intraoperative thrombolysis in the treatment of acute limb ischaemia. Ischemic neurosensory deficit in patients; Problems associated with streptokinase; Indications of thrombolysis; Need to develop a method to evaluate of intraoperative streptokinase.

  • Eye on the Literature.  // Formulary;May2002, Vol. 37 Issue 5, p230 

    Presents some published studies of interest to drug decision-makers. Effect of thrombolytics to elderly patients; Result of the hypericum perforatum test; Study on the effect of longer thromboembolism prophylaxis medication after surgery.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics